Perseus Proteomics Inc.

University of Miyazaki

Fujifilm Ri Pharma Co., Ltd.

Pdradiopharma Inc.

Fumiko Nomura

Katsuyuki Mitomo

Keisuke Ishii

Yoshikazu Kurosawa

Katsushi Kouda

Gene Kurosawa

Kazuhiro Morishita

Lilin Zhang

Yoko Kayukawa

Yoshinori Ukai

Yukio Sudo

Tadashi Matsuura

Hirokazu Satoh

Akihiro Hino

Akio Nagano

Masahiko Watanabe

Tadasi Matsuura

It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent.

Drug conjugate comprising anti-CDH3 (P-cadherin) antibody

The present invention provides an anti-CDH3 humanized antibody having lower immunogenicity, and an anti-CDH3 humanized antibody drug conjugate having the aforementioned anti-CDH3 humanized antibody. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody having complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No. NITE BP-1536, and complementarity determining region sequences derived from the light chain variable region thereof, and which also comprises a heavy chain human subgroup III consensus framework sequence or a human germline sequence selected under optimal alignment as a framework region sequence of the heavy chain variable region, and a light chain human &#x3ba; subgroup I consensus framework sequence or a human germline sequence selected under optimal alignment as a framework region sequence of the light chain variable region.

Anti-CDH3 humanized antibody, drug conjugate thereof, and use thereof

An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).

Antibody capable of specifically recognizing transferrin receptor

The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.

An object of the present invention is to provide a radioactive metal anti-cadherin antibody which is highly accumulated specifically in cancer tissue. Another object is to provide a cancer therapeutic agent having high anti-cancer effect and safety and a cancer diagnostic agent. The radioactive metal-labeled anti-cadherin antibody is obtained by binding a radioactive metallic element to an anti-cadherin antibody via a metal-chelating reagent.

Radioactive metal-labeled anti-cadherin antibody

Growing community of inventors

Tokyo, Japan

Fumiko Nomura